Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE) (eSAGE)

March 5, 2024 updated by: Douglas Scharre, Ohio State University

The Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify both Mild Cognitive Impairment (MCI) and early dementia. SAGE's self-administered feature, pen and paper format, and four equivalent interchangeable forms allows it to be given in almost any setting, does not require any staff time to administer and makes it practical to rapidly screen large numbers of individuals in the community or in their home.This trial is being conducted to study the validity of SAGE in a digital format (eSAGE) for cognitive screening.

The investigators will analyze the data to learn the correlations between eSAGE and gold standard neuropsychological testing designed to differentiate normal cognition from MCI and early dementia. The investigators will also find out whether the paper (SAGE) and electronic (eSAGE) versions of SAGE could be used interchangeably or not.

Addendum:

The eSAGE was previously validated in an earlier stage of this trial. It was initially designed for tablet use and the exact same test has recently been formatted for smartphone use.

This addendum is being conducted to study the validity of the smartphone eSAGE compared to the tablet eSAGE for cognitive screening.

Study Overview

Status

Active, not recruiting

Detailed Description

Participants will be recruited based on their eSAGE scores and evaluated with neuropsychological testing and medical history to determine their status as normal, mild cognitive impairment, or dementia.

The investigators will analyze the data to learn the correlations between eSAGE and gold standard neuropsychological testing designed to differentiate normal cognition from MCI and early dementia. The investigators will also find out whether the paper (SAGE) and electronic (eSAGE) versions of SAGE could be used interchangeably or not.

Addendum:

Subjects will be scheduled for a one time visit where they will be administered both the tablet eSAGE and the smartphone eSAGE. eSAGE tablet scores will be compared to eSAGE smartphone scores to determine if the two formats are equivalent to each other.

Study Type

Observational

Enrollment (Actual)

69

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ohio
      • Columbus, Ohio, United States, 43221
        • The Ohio State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Subjects will be recruited from a wide variety of community events including senior centers, health fairs, educational talks to lay public, independent and assisted living facilities, and free memory screens as well as from ambulatory Geriatric or Memory Disorders Clinics. The SAGE cognitive screening tool will be given to all subjects willing to take the test.Participants who complete the SAGE test and meet inclusion and exclusion criteria will be divided into groups based on their initial SAGE scores. Each group will be composed of subjects with the same score. Individuals will be randomly selected from each group and asked to further participate in a one-time clinical evaluation.

Addendum:

Subjects will be recruited from community events and our clinic and research center.

Description

Inclusion Criteria:

  • Adults over 49 years old of either gender
  • Vision and hearing sufficient for compliance with tests

Exclusion Criteria:

  • Diagnosis by a physician of moderate or severe dementia
  • Intellectual disability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
eSAGE score of 10
Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 11
Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 12
Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 13
Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 14
Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 15
Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 16
Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 17
Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 18
Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 19
Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 20
Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 21
Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 22
Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 9
Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 8
Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 6
Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 7
Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 5
Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 4
Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 3
Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
eSAGE score of 2
Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
standard neuropsychological testing including brief standardized assessments
Smartphone eSAGE score of 13
Participants who score a 13 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 14
Participants who score a 14 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 15
Participants who score a 15 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 16
Participants who score a 16 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 17
Participants who score a 17 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 18
Participants who score a 18 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 19
Participants who score a 19 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 20
Participants who score a 20 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 21
Participants who score a 21 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
Smartphone eSAGE score of 22
Participants who score a 22 on the smartphone eSAGE. Interventions include neuropsychological testing.
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
eSAGE Score Compared to the Sum of the Neuropsychological Measures.
Time Frame: 3 Hours

Analysis will consist of comparing the subject's scores on the SAGE in digital format to their neuropsychological test scores. This will be a composite score of the neuropsychological testing scores. The neuropsychological measures include:

  • Boston Naming Test
  • Wisconsin Card Sort Task (WCST)
  • Hopkins Verbal Learning Test (HVLT)
  • FAS verbal fluency task
  • Wechsler Adult Intelligence Scale III (WAIS III) Letter-number and block design subtests

Associations will be investigated using Spearman correlations.

3 Hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
eSAGE Score Compared to the Paper SAGE Score
Time Frame: 3 hours
The investigators will compare the subject's scores on the SAGE in digital format to their paper SAGE scores to determine if these two formats are equivalent to each other. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compared to the Mini-Mental State Examination (MMSE) Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores with the Mini-Mental State Examination (MMSE) scores. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compared to the Montreal Cognitive Assessment (MoCA) Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores with the Montreal Cognitive Assessment (MoCA) scores. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compared to the Boston Naming Test Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores to the Boston Naming Test score. The Boston Naming Test consists of 60 pictures of nouns that subjects must try to name. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compared to the Wisconsin Card Sort Task (WCST) Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores to the Wisconsin Card Sort Task (WCST) perseverative errors scores. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compared to the Hopkins Verbal Learning Test (HVLT) Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores to the Hopkins Verbal Learning Test (HVLT) total learning scores. Associations will be investigated using Spearman correlations. The investigators will also compare the eSAGE scores to the Hopkins Verbal Learning Test (HVLT) delayed recall scores. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compare to the FAS Verbal Fluency Task Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores to the FAS Verbal Fluency Task scores. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Letter-number Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores to the WAIS III Letter-number scores. The WAIS III Letter-number test asks subjects to recall a series of numbers in increasing order and letters in alphabetical order. Associations will be investigated using Spearman correlations.
3 hours
eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Block Design Score
Time Frame: 3 hours
The investigators will compare the eSAGE scores to the WAIS III Block Design scores. The WAIS III Block Design requires the replication of red and white designs using three-dimensional colored blocks. Associations will be investigated using Spearman correlations.
3 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Douglas Scharre, M.D., Ohio State University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

January 1, 2026

Study Registration Dates

First Submitted

March 18, 2015

First Submitted That Met QC Criteria

September 4, 2015

First Posted (Estimated)

September 9, 2015

Study Record Updates

Last Update Posted (Actual)

March 8, 2024

Last Update Submitted That Met QC Criteria

March 5, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2014H0039

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dementia

Clinical Trials on neuropsychological testing

3
Subscribe